Kirkland Represents Parexel and Pamplona on $8.5 Billion Sale of Parexel to EQT Private Equity and Goldman Sachs Asset Management

Kirkland & Ellis advised Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, and Pamplona Capital Management LP on Parexel’s sale to EQT IX fund and the Private Equity business within Goldman Sachs Asset Management for $8.5 billion. The transaction is subject to customary closing conditions. 

Read the Parexel press release

The Kirkland team was led by corporate partners Lauren Colasacco, Frances Dales and Peter Martelli.